Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical enforcement Erik Lundgren arsenic its main enforcement serviceman arsenic the institution advances its aggregate sclerosis attraction campaigner done late-stage improvement and prepares for imaginable commercialization.

He succeeds Daniel Vitt, who volition proceed to oversee technological strategy and portfolio advancement portion remaining connected the company’s committee of directors.

Immunic’s committee seat Michael Bonney said Lundgren’s enactment acquisition would enactment the company’s modulation toward becoming a commercial-stage biotechnology company.

Immunic is processing vidofludimus calcium, an oral therapy campaigner for neurologic diseases, including relapsing aggregate sclerosis (RMS) and superior progressive aggregate sclerosis (PPMS). The institution is presently conducting the pivotal signifier 3 ENSURE programme successful RMS and plans to motorboat a signifier 3 programme successful PPMS.

Lundgren joins Immunic from Genentech, portion of the Roche Group, wherever helium astir precocious served arsenic elder vice president of the Commercial Portfolio Organization. In that role, helium oversaw commercialized strategy crossed the company’s therapeutic portfolio.

He besides antecedently served arsenic wide manager of Roche Czech Republic and held enactment positions wrong Roche’s neuroscience business, including enactment related to Huntington’s disease.

During much than a decennary astatine Genentech, Lundgren held respective commercialized enactment roles, including elder selling manager for the motorboat and commercialization of Ocrevus (ocrelizumab), a attraction for RMS and PPMS. He besides worked connected oncology merchandise launches, including Kadcyla and Zelboraf.

In a statement, Lundgren said Immunic’s pb campaigner offers a perchance differentiated attack to treating some relapsing and progressive forms of aggregate sclerosis by targeting immunological and neuroprotective pathways.

“Having spent my vocation focused connected bringing innovative medicines to patients, including those with MS, I judge Immunic is uniquely positioned to beforehand this important programme done late-stage improvement and imaginable commercialization,” Lundgren said.

Vitt said Lundgren’s acquisition successful aggregate sclerosis and commercialization would beryllium important arsenic the institution advances vidofludimus calcium done late-stage improvement and prepares for aboriginal commercialization efforts.

“As we attack these important milestones and proceed our improvement toward becoming a commercial-stage biotechnology company, I americium convinced that Erik is the close person to usher Immunic into its adjacent chapter,” Vitt said.